| The glucocorticoid receptor is a key player for prostate cancer cell survival and a target for improved antiandrogen therapy M Puhr, J Hoefer, A Eigentler, C Ploner, F Handle, G Schaefer, J Kroon, ... Clinical Cancer Research 24 (4), 927-938, 2018 | 161 | 2018 |
| The immunosuppressive cytokine interleukin-4 increases the clonogenic potential of prostate stem-like cells by activation of STAT6 signalling G Nappo, F Handle, FR Santer, RV McNeill, RI Seed, AT Collins, ... Oncogenesis 6 (5), e342-e342, 2017 | 93 | 2017 |
| Single-cell ATAC and RNA sequencing reveal pre-existing and persistent cells associated with prostate cancer relapse S Taavitsainen, N Engedal, S Cao, F Handle, A Erickson, S Prekovic, ... Nature communications 12 (1), 5307, 2021 | 74 | 2021 |
| IL6 sensitizes prostate cancer to the antiproliferative effect of IFNα2 through IRF9 HHH Erb, RV Langlechner, PL Moser, F Handle, T Casneuf, K Verstraeten, ... Endocrine-related cancer 20 (5), 677, 2013 | 64 | 2013 |
| Critical role of androgen receptor level in prostate cancer cell resistance to new generation antiandrogen enzalutamide J Hoefer, M Akbor, F Handle, P Ofer, M Puhr, W Parson, Z Culig, ... Oncotarget 7 (37), 59781, 2016 | 63 | 2016 |
| Drivers of AR indifferent anti-androgen resistance in prostate cancer cells F Handle, S Prekovic, C Helsen, T Van den Broeck, E Smeets, L Moris, ... Scientific reports 9 (1), 13786, 2019 | 57 | 2019 |
| PIAS1 is a determinant of poor survival and acts as a positive feedback regulator of AR signaling through enhanced AR stabilization in prostate cancer M Puhr, J Hoefer, A Eigentler, D Dietrich, G Van Leenders, B Uhl, ... Oncogene 35 (18), 2322-2332, 2016 | 49 | 2016 |
| SOCS3 Modulates the Response to Enzalutamide and Is Regulated by Androgen Receptor Signaling and CpG Methylation in Prostate Cancer Cells F Handle, HHH Erb, B Luef, J Hoefer, D Dietrich, W Parson, G Kristiansen, ... Molecular Cancer Research 14 (6), 574-585, 2016 | 45 | 2016 |
| The STAT3 Inhibitor Galiellalactone Reduces IL6-Mediated AR Activity in Benign and Malignant Prostate Models F Handle, M Puhr, G Schaefer, N Lorito, J Hoefer, M Gruber, ... Molecular cancer therapeutics 17 (12), 2722-2731, 2018 | 38 | 2018 |
| Molecular underpinnings of enzalutamide resistance S Prekovic, T Van den Broeck, S Linder, ME van Royen, AB Houtsmuller, ... Endocrine-related cancer 25 (11), R545-R557, 2018 | 34 | 2018 |
| Mechanistic rationale for MCL1 inhibition during androgen deprivation therapy FR Santer, HHH Erb, SJ Oh, F Handle, GE Feiersinger, B Luef, H Bu, ... Oncotarget 6 (8), 6105, 2015 | 34 | 2015 |
| The stem cell inhibitor salinomycin decreases colony formation potential and tumor‐initiating population in docetaxel‐sensitive and docetaxel‐resistant prostate cancer cells M Gruber, F Handle, Z Culig The Prostate 80 (3), 267-273, 2020 | 30 | 2020 |
| On the use of frequency-domain reconstruction algorithms for photoacoustic imaging R Schulze, G Zangerl, M Holotta, D Meyer, F Handle, R Nuster, G Paltauf, ... Journal of biomedical optics 16 (8), 086002-086002-6, 2011 | 29 | 2011 |
| The AR/NCOA1 axis regulates prostate cancer migration by involvement of PRKD1 B Luef, F Handle, G Kharaishvili, M Hager, J Rainer, G Janetschek, ... Endocrine-Related Cancer 23 (6), 495-508, 2016 | 26 | 2016 |
| The androgen receptor depends on ligand‐binding domain dimerization for transcriptional activation S El Kharraz, V Dubois, ME van Royen, AB Houtsmuller, E Pavlova, ... EMBO reports 22 (12), e52764, 2021 | 25 | 2021 |
| Targeting the glucocorticoid receptor signature gene Mono Amine Oxidase-A enhances the efficacy of chemo-and anti-androgen therapy in advanced prostate cancer M Puhr, A Eigentler, F Handle, H Hackl, C Ploner, I Heidegger, ... Oncogene 40 (17), 3087-3100, 2021 | 20 | 2021 |
| Assessment of STAT5 as a potential therapy target in enzalutamide-resistant prostate cancer HHH Erb, J Bodenbender, F Handle, T Diehl, L Donix, I Tsaur, M Gleave, ... PLoS One 15 (8), e0237248, 2020 | 20 | 2020 |
| p300 is upregulated by docetaxel and is a target in chemoresistant prostate cancer M Gruber, L Ferrone, M Puhr, FR Santer, T Furlan, IE Eder, N Sampson, ... Endocrine-Related Cancer 27 (3), 187-198, 2020 | 20 | 2020 |
| MYC-mediated ribosomal gene expression sensitizes enzalutamide-resistant prostate cancer cells to EP300/CREBBP inhibitors T Furlan, A Kirchmair, N Sampson, M Puhr, M Gruber, Z Trajanoski, ... The American Journal of Pathology 191 (6), 1094-1107, 2021 | 18 | 2021 |
| Inhibition of hepatic scavenger receptor-class B type I by RNA interference decreases atherosclerosis in rabbits E Demetz, I Tancevski, K Duwensee, U Stanzl, E Huber, C Heim, ... Atherosclerosis 222 (2), 360-366, 2012 | 16 | 2012 |
Zoran CuligProfessor of Experimental Urology, Medical University of Innsbruck在 i-med.ac.at 的电子邮件经过验证
